Abstract: A method, controller, and non-transitory computer-readable medium of a distributed crypto-ledger network, including receiving an instruction to perform an operation between a first user and a second user, the first user corresponding to a first entity that is a member of the distributed crypto-ledger network, the instruction comprising a destination address corresponding to the second user, querying a top-level name registry with the destination address to determine a second entity associated with the destination address, the second entity being a different member of the crypto-ledger network, and executing the operation between the first user and the second user by transmitting execution instructions to the first entity and the second entity, the execution instructions causing a first entity controller to modify data stored on a first distributed crypto-ledger of the first entity, and causing a second entity controller to modify data stored on the second distributed crypto-ledger of the second entity.

Abstract: The invention provides antigen binding domains that bind myeloid cell surface antigen CD33 protein comprising the antigen binding domains that bind CD33, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Abstract: Systems and/or methods of the present disclosure enable crypto-ledger interoperability using a controller to perform an operation between a first user and a second user on separate entity-specific distributed crypto-ledgers, where the separate entity-specific distributed crypto-ledgers are both operatively linked to a membered common distributed crypto-ledger. The controller burns a first quantity of first entity-specific crypto-tokens from the first entity-specific distributed crypto-ledger and mints a second quantity of the common crypto-tokens on the membered common distributed crypto-ledger, where the first quantity of first entity-specific crypto-tokens and the second quantity of the common crypto-tokens represent an equivalency.

Abstract: Systems and/or methods of the present disclosure enable ledger interoperability using a controller to perform an operation between a first user and a second user on separate entity-specific distributed ledgers, where the separate entity-specific distributed ledgers are both operatively linked to a membered common distributed ledger. The controller burns a first quantity of first entity-specific tokens from the first entity-specific distributed ledger and mints a second quantity of the common tokens on the membered common distributed ledger, where the first quantity of first entity-specific tokens and the second quantity of the common tokens represent an equivalency. The controller moves the second quantity of common tokens from a first encrypted storage to a second encrypted storage of the membered common distributed ledger, burns the second quantity of the common tokens and mints a third quantity of the second entity-specific tokens on the second entity-specific distributed ledger to complete the operation.

Abstract: Computer-based systems and computer-based methods of present disclosure, in real-time in response to a transmission instruction, mint a token representing the quantity of the asset in a first encrypted storage on a distributed crypto-ledger, the first encrypted storage being associated with a first segregated data structure in a distributed asset network of segregated data structures. The token is moved into a second encrypted storage associated with a second segregated data structure in the distributed asset network. A net quantity of assets associated with the transmission and additional transmissions is determined that represents assets to be moved between the first entity and the second entity to match a net of the movement of tokens associated with each transmission, and the net transmission is instructed in order to move the net quantity of assets between the first entity and the second entity.

Abstract: Systems and/or methods of the present disclosure enable ledger interoperability using a controller to perform an operation between a first user and a second user on separate entity-specific distributed ledgers, where the separate entity-specific distributed ledgers are both operatively linked to a membered common distributed ledger. The controller burns a first quantity of first entity-specific tokens from the first entity-specific distributed ledger and mints a second quantity of the common tokens on the membered common distributed ledger, where the first quantity of first entity-specific tokens and the second quantity of the common tokens represent an equivalency. The controller moves the second quantity of common tokens from a first encrypted storage to a second encrypted storage of the membered common distributed ledger, burns the second quantity of the common tokens and mints a third quantity of the second entity-specific tokens on the second entity-specific distributed ledger to complete the operation.

Abstract: Systems and methods for water based phenolic binders for silicon-dominant anodes may include an electrode coating layer on a current collector, where the electrode coating layer is formed from silicon and a pyrolyzed water-based phenolic binder. The water-based phenolic binder may include phenolic/resol type polymers crosslinked with poly(methyl vinyl ether-alt-maleic anhydride), poly(methyl vinyl ether-alt-maleic acid), and/or Poly(acrylamide-co-diallyldimethylammonium chloride) (PDADAM). The electrode coating layer may further include conductive additives. The current collector may comprise one or more of a copper, tungsten, stainless steel, and nickel foil in electrical contact with the electrode coating layer. The electrode coating layer may include more than 70% silicon. The electrode may be in electrical and physical contact with an electrolyte, where the electrolyte includes a liquid, solid, or gel. The battery electrode may be in a lithium ion battery.

Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.

Abstract: Monoclonal anti-TfR antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are described. Also described are conjugates and fusion constructs containing the anti-TfR antibody or antigen-binding fragment thereof coupled to a therapeutic or diagnostic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detecting a neurological disorder and/or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids encoding the antibodies, conjugates and fusion constructs and related recombinant host cells.

Abstract: Monoclonal anti-CD98 antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are described. Also described are conjugates and fusion constructs containing the anti-CD98 antibody or antigen-binding fragment thereof coupled to a therapeutic or diagnostic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detecting a neurological disorder and/or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids encoding the antibodies, conjugates and fusion constructs and related recombinant host cells.

Abstract: Anti-TRGV9 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Abstract: Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.

Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.

Abstract: The invention encompasses a nontoxic agricultural formulation of a concentrated liquid suspension comprising a drying oil and suspended particulate materials further comprising an additional material; and also encompasses an aqueous formulation comprising the concentrated liquid suspension and an agricultural treatment agent. The invention additionally encompasses methods of treating an agricultural target.

Abstract: A clamping device for a multilayered battery comprising one or more electrochemical cells is provided. The clamping device can include one or more plates, guided elastic members, and/or one or more layers of an interfacial material, such as foam pads or papers, to provide distributed pressure across one or more surfaces of the multilayered battery during cell formation and/or cycling. A compression plate is employed to provide a compressive force to compress the elastic members to a predetermined length, at which the position of the elastic members can be fixed.

Abstract: Systems and/or methods of the present disclosure enable crypto-ledger interoperability using a controller to perform an operation between a first user and a second user on separate entity-specific distributed crypto-ledgers, where the separate entity-specific distributed crypto-ledgers are both operatively linked to a membered common distributed crypto-ledger. The controller burns a first quantity of first entity-specific crypto-tokens from the first entity-specific distributed crypto-ledger and mints a second quantity of the common crypto-tokens on the membered common distributed crypto-ledger, where the first quantity of first entity-specific crypto-tokens and the second quantity of the common crypto-tokens represent an equivalency.

Abstract: Systems and methods utilizing aqueous-based polymer binders for silicon-dominant anodes may include an electrode coating layer on a current collector, where the electrode coating layer is formed from silicon and an aqueous-based suspension-solution binder composition comprising a water soluble (aqueous-based) polymer as part of a multi-component binder composition that also contains an water insoluble polymer. The electrode coating layer may include more than 70% silicon and the anode may be in a lithium ion battery.

Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Abstract: An adjustable bra and method of adjusting the same are provided. The adjustable bra includes a bra garment with a plurality of garment adjusters. Each garment adjuster is configured to adjust at least one adjustable bra feature relating to at least one of the fit or support of the bra garment. The adjustable bra also includes an adjustment mechanism configured with a plurality of adjustment positions. The adjustment mechanism is movable between a plurality of positions corresponding to the garment adjuster position of each garment feature and the adjustment mechanism also includes a singular adjustment point configured to move the garment adjusters between different positions. A corresponding method of adjusting the adjustable bra is also provided.

Abstract: A method for formation of cylindrical and prismatic can cells may include providing a battery, where the battery includes one or more cells, with each cell including at least one silicon-dominant anode, a cathode, and a separator. The battery also includes a metal can that contains the one or more cells such that during formation a pressure between 50 kPa and 1 MPa is applied to the one or more cells. The battery may include strain absorbing materials arranged between the one or more cells and interior walls of the can. The strain absorbing materials may include foam. The strain absorbing materials may include a solid electrolyte layer. The strain absorbing materials may include PMMA, PVDF, or a combination thereof. The pressure during a formation process may be due to a thickness of the strain absorbing materials being thicker than an expansion of the one or more cells.